The pipeline for Inflammatory Bowel Disease is currently lucrative, consisting of many key assets in the late stage of development. Some of the most promising emerging therapies in the pipeline include Mirikizumab, Filgotinib, and others. Major pharma and biotech giants such as Takeda, Eli Lilly, Gilead, AstraZeneca, and others are actively working in the Inflammatory Bowel Disease therapeutics market.
DelveInsight’s “Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Inflammatory Bowel Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Inflammatory Bowel Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Inflammatory Bowel Disease: An Overview
Inflammatory Bowel Disease (IBD) is a complex chronic disease resulting from the dysregulation of the immune system triggered by genetic, epigenetic, microbial, and environmental factors. Ulcerative colitis (UC) and Crohn’s disease (CD) are two forms of inflammatory bowel disease that can cause serious and debilitating symptoms and disruptions in daily life.
Ulcerative colitis occurs when the immune system sends white blood cells into the lining of the intestines, where they produce chronic inflammation and ulcerations. There is an unmet need for additional treatment options for Ulcerative colitis that provide meaningful symptom relief, including bowel urgency, and deliver sustained clinical remission. Crohn’s disease is a chronic immune-mediated condition of the gastrointestinal (GI) tract. Crohn’s most commonly affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the GI tract, from the mouth to the anus. Inflammatory Bowel Disease, including Crohn’s disease and Ulcerative colitis, affects approximately 10 million people worldwide.
Inflammatory Bowel Disease Market Key Facts
In the 7MM, there were ~3,835,000 prevalent cases of Inflammatory Bowel Disease in total during the year 2021. This count is anticipated to increase during the forecast period over all the geographies.
In the EU-5 region, there were ~634,000 and ~1,021,000 prevalent cases of Crohn’s disease and Ulcerative colitis, respectively, in 2021.
In 2021, in Germany, there were ~357,000 prevalent cases of Ulcerative Colitis (UC), and ~227,000 cases were recorded for Crohn’s disease (CD).
Japan accounted for ~331,000 prevalent cases of Inflammatory Bowel Disease in 2021, which makes up around 9% of the total Inflammatory Bowel Disease cases in the 7MM. Out of all the prevalent cases in Japan, there were around 72% diagnosed with prevalent cases of Inflammatory Bowel Disease in 2021.
Inflammatory Bowel Disease Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Inflammatory Bowel Disease market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Inflammatory Bowel Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Inflammatory Bowel Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Inflammatory Bowel Disease Epidemiology, Segmented as –
Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM [2019–2032]
Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM [2019–2032]
Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) (e.g., Ulcerative colitis, Crohn’s Disease, and Unspecified) in the 7MM [2019–2032]
Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM [2019–2032]
Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM [2019–2032]
Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Inflammatory Bowel Disease market or expected to be launched during the study period. The analysis covers the Inflammatory Bowel Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Inflammatory Bowel Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Inflammatory Bowel Disease Market Will Evolve and Grow by 2032 @
Inflammatory Bowel Disease Therapeutics Analysis
The goal of inflammatory bowel disease treatment is to reduce the inflammation that triggers your signs and symptoms. In the best cases, this may lead not only to symptom relief but also to long-term remission and reduced risks of complications. Inflammatory Bowel Disease treatment usually involves either drug therapy or surgery. Anti-inflammatory drugs are the first step in Inflammatory Bowel Disease treatment. These drugs help decrease inflammation of the digestive tract. However, they have many side effects.
Several major pharma and biotech giants are actively working in the Inflammatory Bowel Disease Therapeutics Market to improve the treatment scenario.
Leading Companies in the Inflammatory Bowel Disease Therapeutics Market Include:
Eli Lilly and Company
Applied Molecular Transport
And Many Others
Inflammatory Bowel Disease Emerging and Marketed Therapies Covered in the Report Include:
Stelara (ustekinumab): Janssen Pharmaceuticals
Humira (adalimumab): Abbvie
Mirikizumab: Eli Lilly and Company
AMT-101: Applied Molecular Transport
Tremfya (guselkumab): Janssen
JYSELECA (filgotinib): Gilead/Galapagos
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Inflammatory Bowel Disease Competitive Intelligence Analysis
4. Inflammatory Bowel Disease Market Overview at a Glance
5. Inflammatory Bowel Disease Disease Background and Overview
6. Inflammatory Bowel Disease Patient Journey
7. Inflammatory Bowel Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Inflammatory Bowel Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Inflammatory Bowel Disease Unmet Needs
10. Key Endpoints of Inflammatory Bowel Disease Treatment
11. Inflammatory Bowel Disease Marketed Products
12. Inflammatory Bowel Disease Emerging Drugs and Latest Therapeutic Advances
13. Inflammatory Bowel Disease Seven Major Market Analysis
14. Attribute Analysis
15. Inflammatory Bowel Disease Market Outlook (In US, EU5, and Japan)
16. Inflammatory Bowel Disease Access and Reimbursement Overview
17. KOL Views on the Inflammatory Bowel Disease Market
18. Inflammatory Bowel Disease Market Drivers
19. Inflammatory Bowel Disease Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States